DaVita Inc. DVA SPXR3KPHARMA

Q: What is the current share price of DaVita Inc. (DVA)?

As of 2026-09-07 16:24 PDT, DaVita Inc. (DVA) trades at $183.99 on NYSE. Its 52-week range is $103.87 to $240.96.

Q: What is the market capitalisation of DVA?

DaVita Inc. (DVA) has a market capitalisation of $11.81B on NYSE.

Q: What is the P/E ratio of DVA?

DVA trades at a trailing price-to-earnings (P/E) ratio of 15.59. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -15.36.

Q: What is the return on equity (ROE) of DVA?

DVA has a return on equity (ROE) of 88.48%. Its return on capital employed (ROCE) is 14.02%.

Q: Is DVA a good stock to buy?

This page provides a data-driven analysis of DaVita Inc. (DVA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Care Facilities · United States

https://www.davita.com

Company Profile ↓

$183.99

+36.60% 1Y

Mkt Cap$11.81B

P/E15.59

P/B-15.36

52W High$240.96

52W Low$103.87

Book Value$-11.96

EPS (TTM)$11.80

Company Overview

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 88.5%, reflecting efficient use of shareholder capital.

Reasonable Valuation

Trades at a P/E of 15.6, below the sector median of 25.2.

Healthy Margins

Operating margin of 16.1% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $13.64B (+6.5% YoY); net profit $746.80M.
Trailing 12 Months Year-on-year growth — revenue +5.2%, earnings +55.8%.
5-Year Trend Long-term compounding — revenue CAGR 3.1%, profit CAGR 4.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	3.07%
1 Year:	5.20%

Compounded Profit Growth

5 Years:	4.03%
1 Year:	55.80%

Stock Price Performance

1 Year:	+36.60%
6 Months:	+22.04%
3 Months:	-4.25%
1 Month:	+1.84%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 58% of range

$103.87 $240.96

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMAAbove
RSI (14)44.14 · Neutral

Price Performance

1M+1.84%

3M-4.25%

6M+22.04%

1Y+36.60%

Valuation vs Sector

P/E of 15.59 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 88.5%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

15.59

Industry PE

25.17

Forward P/E

10.77

PEG Ratio

0.56

Book Value

$-11.96

Price to Book

-15.36

P/S

0.84

EV/EBITDA

9.30

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

3.07%

Profit 5Y

4.03%

Revenue (YoY)

5.20%

Earnings (YoY)

55.80%

Profitability & Returns

ROCE

14.02%

ROE

88.48%

ROA

7.51%

Profit Margin

6.05%

Op Margin

16.06%

Gross Margin

32.36%

EPS (Latest Qtr)

$4.02

EPS (TTM)

$11.80

Balance Sheet & Liquidity

Debt/Equity

12.42

Quick Ratio

1.33

Current Ratio

1.47

Debt

$13.41B

Total Assets

$17.71B

Current Assets

Working Capital

Ownership

Promoter Holding

46.91%

Chg in Prom Hold

0.00%

FII / Inst Holding

49.33%

Chg in FII Hold

0.00%

Financial Snapshot

Enterprise Value

$11.81B

Total Revenue (TTM)

$14.01B

EBITDA

$2.83B

Free Cash Flow

$1.04B

Operating Cash Flow

$2.19B

Shares Outstanding

64.19M

Gross Margin

32.36%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	DVA DaVita Inc. SPXR3KPHARMA	183.99	15.59	$11.81B	0.00%	14.02%	88.48%	3.07%	4.03%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	2.63B	2.70B	2.77B	2.78B	2.85B	2.89B	2.85B	2.82B	2.74B	2.84B	2.90B	2.90B	2.84B	2.88B	2.92B	2.91B	2.82B	2.92B	2.94B	2.82B	2.93B	2.95B	2.87B	3.00B	3.12B	3.07B	3.19B	3.26B	3.22B	3.38B	3.42B	3.42B	3.55B
Operating Income	480.55M	509.37M	244.94M	422.03M	431.13M	813.10M	363.44M	875.93M	391.20M	395.29M	150.34M	410.69M	438.19M	289.04M	387.91M	340.51M	461.89M	378.34M	462.59M	465.38M	409.92M	437.67M	381.67M	442.60M	490.48M	474.88M	338.31M	432.71M	311.79M	311.64M	405.29M	495.94M	483.85M	506.40M	534.88M	438.94M	537.84M	505.77M	481.89M	579.00M
Net Income	170.48M	215.87M	-6.00M	97.43M	53.38M	571.33M	157.73M	447.70M	127.00M	-214.48M	303.40M	178.69M	267.28M	-136.80M	-149.77M	149.29M	273.55M	143.27M	244.87M	239.59M	201.60M	158.67M	173.77M	237.40M	293.82M	259.75M	162.12M	224.81M	105.37M	115.55M	178.69M	246.63M	239.65M	222.68M	214.69M	162.92M	199.34M	150.33M	197.53M	265.40M
Diluted EPS	0.78	1.00	-0.03	0.47	0.26	2.76	0.80	2.29	0.65	-1.12	1.64	0.98	1.53	-0.82	-0.90	0.90	1.64	0.95	1.88	1.89	1.62	1.28	1.50	2.09	2.64	2.36	1.61	2.30	1.13	1.25	1.91	2.62	2.65	2.50	2.50	2.00	2.58	2.04	2.87	4.02

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	10.71B	10.88B	11.40B	11.39B	11.55B	-	11.61B	12.14B	12.82B	13.64B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.21B	8.32B	8.60B	9.24B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.40B	3.82B	4.22B	4.40B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.09B	2.22B	2.26B	2.39B
Operating Income	908.91M	869.10M	939.63M	993.81M	1.15B	1.30B	1.55B	1.82B	1.14B	2.03B	1.81B	1.53B	1.64B	1.69B	-	1.31B	1.60B	1.95B	2.01B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.06B	2.32B	2.72B	2.64B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	357.02M	398.55M	470.47M	579.93M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	966.28M	1.18B	1.53B	1.35B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	198.09M	220.12M	279.66M	293.11M
Net Income	381.78M	374.16M	422.68M	405.68M	478.00M	536.02M	633.45M	723.11M	269.73M	879.87M	663.62M	159.39M	810.98M	773.64M	-	560.40M	691.53M	936.34M	746.80M
Diluted EPS	3.55	3.53	4.06	3.94	2.48	2.74	2.95	3.33	1.25	4.29	3.47	0.92	5.27	6.31	-	5.85	7.42	10.73	9.84

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	7.29B	7.56B	8.11B	8.90B	16.01B	17.10B	17.62B	18.51B	18.76B	18.97B	19.11B	17.31B	16.99B	17.12B	16.93B	16.89B	17.29B	17.48B
Total Equity	-	-	1.77B	2.14B	1.98B	2.14B	3.76B	4.43B	5.17B	4.87B	4.65B	4.69B	3.70B	2.13B	1.38B	755.51M	712.33M	1.06B	121.12M	-651.08M
Cash & Equivalents	310.20M	447.05M	410.88M	539.46M	860.12M	393.75M	533.75M	946.25M	736.90M	1.24B	674.78M	508.23M	323.04M	1.10B	324.96M	461.90M	244.09M	380.06M	794.93M	676.44M
Long Term Debt	-	-	3.62B	3.53B	4.23B	4.42B	8.55B	8.42B	8.50B	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	5.17B	5.03B	5.69B	6.16B	11.52B	11.80B	11.43B	12.57B	12.93B	13.08B	14.08B	13.81B	14.09B	14.75B	14.70B	14.15B	15.19B	16.32B
Current Liabilities	-	-	1.16B	1.05B	924.35M	1.16B	2.02B	2.46B	2.09B	2.40B	2.71B	3.07B	4.89B	2.37B	2.48B	2.40B	2.62B	2.64B	2.97B	3.14B

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	581.07M	613.70M	666.71M	839.68M	1.18B	1.10B	1.77B	1.46B	1.56B	1.97B	1.91B	1.77B	2.07B	1.98B	1.93B	1.56B	2.06B	2.02B	1.89B
Investing Cash Flow	-446.74M	-397.74M	-346.06M	-436.63M	-1.40B	-4.83B	-876.88M	-1.28B	-881.78M	-1.20B	-1.36B	-1.01B	3.00B	-825.37M	-784.73M	-630.35M	-771.80M	-771.43M	-654.95M
Financing Cash Flow	2.52M	-252.13M	-192.07M	-82.39M	-247.18M	3.87B	-482.99M	-164.98M	-138.97M	-1.35B	-766.26M	-625.35M	-4.70B	-1.85B	-1.08B	-1.12B	-1.17B	-816.94M	-1.37B
Capital Expenditure	-272.21M	-317.96M	-274.61M	-273.60M	-400.16M	-550.15M	-617.60M	-641.33M	-708.00M	-829.10M	-905.25M	-987.14M	-766.55M	-674.54M	-641.47M	-603.43M	-567.99M	-555.44M	-575.86M
Free Cash Flow	308.85M	295.74M	392.11M	566.08M	779.89M	550.70M	1.16B	818.08M	849.20M	1.14B	1.01B	784.50M	1.31B	1.30B	1.29B	961.14M	1.49B	1.47B	1.31B
Share Buybacks	6.35M	232.72M	153.50M	618.50M	323.35M	-	-	-	549.93M	1.10B	802.95M	1.16B	2.38B	1.46B	1.54B	802.23M	272.22M	1.39B	1.31B

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	29.3%	31.5%	32.9%	32.2%
Operating Margin %	-	-	-	-	-	-	-	-	-	19.0%	16.7%	13.4%	14.4%	14.7%	-	11.3%	13.2%	15.3%	14.7%
Net Margin %	-	-	-	-	-	-	-	-	-	8.2%	6.1%	1.4%	7.1%	6.7%	-	4.8%	5.7%	7.3%	5.5%
ROE %	-	21.2%	19.8%	20.5%	22.3%	14.2%	14.3%	14.0%	5.5%	18.9%	14.1%	4.3%	38.0%	55.9%	-	78.7%	65.5%	773.1%	-114.7%
ROCE %	-	14.2%	14.4%	13.8%	14.9%	9.3%	10.6%	11.7%	7.1%	12.7%	11.4%	10.7%	11.0%	11.7%	-	9.2%	11.2%	13.7%	14.0%

Shareholding Pattern

Insiders

46.91%

Institutions

49.33%

Public Float

92.92%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Berkshire Hathaway, Inc	45.27%	28.88M	$5.22B
2	Blackrock Inc.	3.86%	2.46M	$444.65M
3	Vanguard Capital Management LLC	3.29%	2.10M	$379.69M
4	Morgan Stanley	2.51%	1.60M	$289.40M
5	Vanguard Portfolio Management LLC	2.16%	1.38M	$248.96M
6	State Street Corporation	2.07%	1.32M	$239.04M
7	Invesco Ltd.	1.90%	1.21M	$218.97M
8	Dimensional Fund Advisors LP	1.78%	1.14M	$205.58M
9	Neuberger Berman Group, LLC	1.45%	925.58K	$167.23M
10	LSV Asset Management	1.42%	908.39K	$164.13M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for DVA

Google News Mon, 07 Sep 2026

DaVita Inc. (DVA) Stock Analysis: Evaluating the 18.72% Upside Potential for Healthcare Investors - DirectorsTalk Interviews

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOS080V2lFY1lGTWduLTVybjhHSlJrOThUdC1wUmtWQVdFZHBhN0JMV0dsZWdIREpZbXV2OUxMS3B1ZnRQcjJERDlxRG1tcTNoeGpFYXlna25sRVZ5X2ZKMXA2bWp0OUlGSTVlNWlsZ2dGZ1RYcEduTmJwTnVfdGUtM2NYTkc1NENFc1V5Sl…

Google News hu, 30 Jul 2026

DaVita (DVA) Stock Sees Fair Value Lift After Analyst Target Increases - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOZC1DaVlCSlpncG9KbEhBOV9VeHJyZFYxVlZEenBXc2cyOEZseXlmbTc5UUNkeFdnWXIzVlVtODF1SHFPaElmQWtJdXl1WGdKTHVPUVpPRXVnYURIa0RoR3R5WEFFaGZCMzFMY29sRHRXek1fVlROUmhNV3prUHFMZk5WaHY0RkdES2dqcE…

Google News Wed, 05 Aug 2026

DaVita Stock Drops Despite Reporting Strong Q2 Results and Solid Guidance - TIKR.com

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9Nc0NHLURDZW1Pd1Fud1hFY2dlemZBcy1NUk13Y3ZydE1laTV1TnhoQm9jcXcwZ2poTkdoa1VUa01wcnZ0VEVXNGFCVDh0X0lmZHdRN2pUSFlSVE5qNEdzSE9KLWU5aWRZS1RsaVI3NGdxRjZ5anEtYnlOdW16N2M?oc=5" target="_bla…

Google News Fri, 04 Sep 2026

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - Eastern Progress

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNTHVDTEVIenhlR3RXdWNsZ3lmSzhweXd5RzJUeHVGYzRUZmY5T2hwTHBhU2Q3UTJ4UXJXenVLNlBqMDY1Q1ktNWc2Rkp1LTE4Sy1LNDM4LWptUnJ3M1JhcHR6T0RLTV9aTFh3OVloR3ltaGpkQi1QWFBPM0FKdEdLMHIzM0xDU1lsM0JNVl…

Google News Sat, 05 Sep 2026

What DaVita (DVA)'s Expanded Humana CKD Partnership Means For Shareholders - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNUmlYUld4cjdVamg5RHdiU1J3RHdLRk9RTnNOOTlkUzdiQmJlZUpsOWpuYWhEaGUxVVZvM1lxaGhka1FNZXBlNTJtUXQ1Y3V6WnJHOUQtQmlDcjhJYXJwTXNaak5FX2lYR1p4RjZrUlY3elk0VFZ4T0ZUSGw1RnNyYWVrOVVHM0UxeEZoWE…

Google News ue, 04 Aug 2026

DaVita (NYSE:DVA) Beats Q2 CY2026 Sales Expectations But Stock Drops - StockStory

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNSzRsalQyWUw2OWVhZUZqcXcyVDdJSVdlaWZLbXNfRlVHZ1FqQllBb3A4TGpOY0ZLY3JzMXYtaGRJazJPeGMtdjA3SlozaGFMdFdJWVFCaThpeHNBNThNOE5SZEpySGh1ZGcxWHBzV0VYSG8yZkJwWG5FaFd2VGNySjItLTB5YUhCSjJSN0…

DVA — Frequently Asked Questions

What is the current share price of DaVita Inc. (DVA)?

As of 2026-09-07 16:24 PDT, DaVita Inc. (DVA) trades at $183.99 on NYSE. Its 52-week range is $103.87 to $240.96.

What is the market capitalisation of DVA?

DaVita Inc. (DVA) has a market capitalisation of $11.81B on NYSE.

What is the P/E ratio of DVA?

DVA trades at a trailing price-to-earnings (P/E) ratio of 15.59. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -15.36.

What is the return on equity (ROE) of DVA?

DVA has a return on equity (ROE) of 88.48%. Its return on capital employed (ROCE) is 14.02%.

Is DVA a good stock to buy?

This page provides a data-driven analysis of DaVita Inc. (DVA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

DaVita Inc. DVA SPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

DaVita Inc. (DVA) Stock Analysis: Evaluating the 18.72% Upside Potential for Healthcare Investors - DirectorsTalk Interviews

DaVita (DVA) Stock Sees Fair Value Lift After Analyst Target Increases - Yahoo Finance

DaVita Stock Drops Despite Reporting Strong Q2 Results and Solid Guidance - TIKR.com

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - Eastern Progress

What DaVita (DVA)'s Expanded Humana CKD Partnership Means For Shareholders - simplywall.st

DaVita (NYSE:DVA) Beats Q2 CY2026 Sales Expectations But Stock Drops - StockStory

DVA — Frequently Asked Questions

What is the current share price of DaVita Inc. (DVA)?

What is the market capitalisation of DVA?

What is the P/E ratio of DVA?

What is the return on equity (ROE) of DVA?

Is DVA a good stock to buy?

Explore More